论文部分内容阅读
目的：探讨影响老年妇女卵巢恶性肿病预后的因素，方法：对我院治疗的136例老年与非老年妇女卵巢恶性肿瘤进行回顾性分析。结果：5年生存车老年组（34例）为32.4％，非老年组（102例）为51．0％．Ⅰ、Ⅱ、Ⅲ期患者两级问5年生存率无显著性差异（P＞0．05），Ⅲ期患者老年级明显低于非老年组（P＜0．01）。根据细胞学分级，老年组5年生存率分别为Ⅰ级71．4％，2级16．7％，3级0；非老年组分别为Ⅰ奴90．0％，2级50．0％，3级14．3％，两组各级间差异均无显著性（P＞0．05）。根据初次手术后残留癌灶大小5年生存车老年组天残留癌者为70．0％．残留癌灶≤2cm者为50．0％，＞2cm者为10．0％；非老年组分别为800％，33．3％．5．6％，两组间比较无显著性差异（P＞0．05）。老年组完成化疗＜6疗程者5年生存率为12．5％，≥6疗程者为50．0％；非老年组分别为20．0％．71．0％，两组间比较天显著性差异（P＞0.05）。结论：卵巢恶性肿瘤患者年龄并非影响预后因素．老年妇女卵巢恶性肿瘤预后与临床分期、细胞分化程度，初次手术后残留癌灶大小、化疗的足量、及时和疗程数密切相关。
Objective: To explore the factors affecting the prognosis of ovarian malignant neoplasms in elderly women.Methods: A retrospective analysis of ovarian malignancies in 136 elderly and non-elderly women treated in our hospital. Results: The 5-year survival car elderly group (34 cases) was 32.4%, while the non-elderly group (102 cases) was 51.0%. There was no significant difference in the 5-year survival rates between stage Ⅰ, Ⅱ and Ⅲ (P> 0.05). The stage Ⅲ patients were significantly lower than those in the non-elderly group (P <0.01). According to the cytological grading, the 5-year survival rates in the elderly group were 71.4% for grade Ⅰ, 16.7% for grade 2 and 0% for grade 3, respectively; 90.0% for grade Ⅰ, 50.0% for grade 2, 3 grade 14.3%, there was no significant difference between the two groups (P> 0.05). According to the size of residual tumor after primary surgery, the residual carcinom of 5-year-old car was 70.0%. Residual cancer ≤ 2cm were 50.0%,> 2cm were 10.0%; non-elderly were 800%, 33.3%. 5.6%, no significant difference between the two groups (P> 0.05). Elderly group completed chemotherapy <6 courses of 5-year survival rate was 12.5%, ≥ 6 courses were 50.0%; non-elderly group were 20.0%. 71.0%, there was a significant difference between the two groups (P> 0.05). Conclusion: The age of patients with ovarian cancer is not a prognostic factor. The prognosis of ovarian cancer in elderly women is closely related to clinical stage, degree of cell differentiation, size of residual cancer after primary surgery, sufficient quantity of chemotherapy, and timely treatment.